Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

2.

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine.

Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A.

Pain Med. 2016 Feb 25. pii: pnv110. [Epub ahead of print]

PMID:
26917621
3.

Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.

Bai SA, Xiang Q, Finn A.

Clin Ther. 2016 Feb;38(2):358-69. doi: 10.1016/j.clinthera.2015.12.016. Epub 2016 Jan 21.

PMID:
26804639
4.

Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.

Darpo B, Zhou M, Bai SA, Ferber G, Xiang Q, Finn A.

Clin Ther. 2016 Feb;38(2):315-26. doi: 10.1016/j.clinthera.2015.12.004. Epub 2015 Dec 31.

PMID:
26749217
5.

Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.

Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A.

Postgrad Med. 2016 Jan;128(1):1-11. doi: 10.1080/00325481.2016.1128307. Epub 2015 Dec 22.

PMID:
26634956
6.

The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease.

Roberts MH, Mapel DW, Thomson HN.

Clinicoecon Outcomes Res. 2015 Mar 26;7:173-84. doi: 10.2147/CEOR.S80424. eCollection 2015.

7.

Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.

Silverman LA, Neely EK, Kletter GB, Lewis K, Chitra S, Terleckyj O, Eugster EA.

J Clin Endocrinol Metab. 2015 Jun;100(6):2354-63. doi: 10.1210/jc.2014-3031. Epub 2015 Mar 24.

8.

EN3427: a novel cationic aminoindane with long-acting local anesthetic properties.

Banerjee M, Baranwal A, Saha S, Saha A, Priestley T.

Anesth Analg. 2015 Apr;120(4):941-9. doi: 10.1213/ANE.0000000000000629.

PMID:
25695675
9.

Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients.

Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE, Kamat AM, Lee CT, Sexton WJ, Steinberg GD.

Bl Cancer. 2015 Oct 26;1(2):143-150.

10.

Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.

Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF.

Ther Adv Urol. 2014 Oct;6(5):181-91. doi: 10.1177/1756287214541798.

11.

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

Morgentaler A, McGettigan J, Xiang Q, Danoff TM, Gould EM.

Int J Impot Res. 2015 Mar-Apr;27(2):41-5. doi: 10.1038/ijir.2014.28. Epub 2014 Jul 24.

PMID:
25056809
12.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group.

Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25.

PMID:
24974051
13.

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.

Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE.

Pain. 2014 Sep;155(9):1683-95. doi: 10.1016/j.pain.2014.05.025. Epub 2014 May 24. Review.

14.

Modern utilization of penile prosthesis surgery: a national claim registry analysis.

Segal RL, Camper SB, Burnett AL.

Int J Impot Res. 2014 Sep-Oct;26(5):167-71. doi: 10.1038/ijir.2014.11. Epub 2014 May 15.

PMID:
24830674
15.

Case fatality and population mortality associated with anaphylaxis in the United States.

Ma L, Danoff TM, Borish L.

J Allergy Clin Immunol. 2014 Apr;133(4):1075-83. doi: 10.1016/j.jaci.2013.10.029. Epub 2013 Dec 14.

16.

Current topics in opioid therapy for pain management: addressing the problem of abuse.

Casty FE, Wieman MS, Shusterman N.

Clin Drug Investig. 2013 Jul;33(7):459-68. doi: 10.1007/s40261-013-0087-8. Review.

PMID:
23740336
17.

Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.

Harnett MD, Shipley J, MacLean L, Schwiderski U, Sandage BW Jr.

Clin Drug Investig. 2013 Feb;33(2):133-41. doi: 10.1007/s40261-012-0039-8.

PMID:
23203138
18.

The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.

Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH.

J Pain. 2012 Jan;13(1):90-9. doi: 10.1016/j.jpain.2011.10.011.

PMID:
22208805
19.

Daily average consumption of 2 long-acting opioids: an interrupted time series analysis.

Puenpatom RA, Szeinbach SL, Ma L, Ben-Joseph RH, Summers KH.

Am Health Drug Benefits. 2012 Jan;5(1):52-60.

20.

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.

Benedek IH, Jobes J, Xiang Q, Fiske WD.

Drug Des Devel Ther. 2011;5:455-63. doi: 10.2147/DDDT.S24372. Epub 2011 Nov 23.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk